The celiac disease treatment market size was valued at USD 682.40 million in 2024 and is expected to reach USD 1667.73 million by 2032, growing at a CAGR of 11.88% over the forecast period of 2025-2032.
The celiac disease treatment market is increasing steadily, fueled by enhanced disease prevalence, better diagnostic facilities, and growing awareness of gluten intolerance. The rising use of gluten-free diets, advancements in enzyme therapies, and favorable regulatory clearances are further fueling the increasing number of treatment options. Additionally, the increasing availability of over-the-counter and prescription-based symptomatic medications further facilitates patient access. Growing markets and future clinical trials for new therapeutic drugs are poised to grow even more rapidly during the forecast period.
The U.S. celiac disease treatment market size was valued at USD 231.15 million in 2024 and is expected to reach USD 547.95 million by 2032, growing at a CAGR of 11.45% over the forecast period of 2025-2032. In 2024, the U.S held the largest share in the North American celiac disease treatment market due to the high incidence of the disease and extensive use of gluten-based foods. For instance, according to NIH, Experts estimate that approximately 2 million people in the United States are affected by celiac disease, and about 1% of the global population lives with the condition. The nation's advanced diagnostic facilities, strong pharmaceutical celiac disease drug companies' presence, and well-developed healthcare infrastructure also favor its position in the celiac disease drug market growth.
Drivers
Increasing Awareness and Early Diagnosis are Propelling the Market Growth
Increased health consciousness about celiac disease has been instrumental in the disease's early detection and management. Public awareness campaigns, health websites, and educational programs are making individuals aware of the symptoms of celiac disease, namely digestive discomfort, skin rashes, and tiredness. Consequently, individuals are approaching their health workers earlier. Timely diagnosis can manage the disease well, averting serious consequences such as malnutrition or other autoimmune diseases. As people become more aware, an increasing number of patients are being diagnosed, which drives demand for treatments and specialty gluten-free foods.
Rising Demand for Gluten-Free Products is Driving the Market Growth
There has been substantial growth in world demand for foods that are free from gluten, not only from those who are diagnosed with celiac disease but also from consumers who do not consume gluten due to other medical reasons, e.g., sensitivity to gluten or overall health. This increasing tendency towards gluten-free living is motivating food companies to produce more diversified gluten-free items, making them more affordable and accessible. In individuals with celiac disease, there is a necessary treatment for their condition, as the intake of gluten can cause serious symptoms and long-term health complications. As such, the increasing availability and demand for the products are hence propelling the celiac disease drug market trends, as sufferers of the disease look for safe, gluten-free options.
In March 2024, The Kraft Heinz Company (US) launched a gluten-free version of its mac 'n' cheese under the name KD Gluten Free, according to Food in Canada and confirmed through a press release. The move forms part of the company's overall shift into plant-based alternatives, which also saw the introduction of KD NotMac and Cheese.
Restraint
Underdiagnosis and Misdiagnosis Restrain the Market Growth
Celiac disease tends to come with symptoms that closely resemble other gastrointestinal or autoimmune illnesses, including irritable bowel syndrome (IBS), lactose intolerance, or Crohn's disease. Non-specific symptoms such as abdominal pain, bloating, fatigue, and diarrhea are given by healthcare professionals to more typical illnesses. Several patients also have atypical or no gastrointestinal symptoms ("silent celiac disease"), further complicating diagnosis. Consequently, a high proportion of cases go undiagnosed.
For Instance, Estimates from the Celiac Disease Foundation suggest that approximately 80% of individuals with celiac disease are undiagnosed in the United States alone. Underdiagnosis creates delays in treatment, lowers patient outcomes, and holds back overall market growth for celiac disease treatment, most notably in regions where fewer diagnostic resources are available.
By Treatment
In 2024, the vitamins & minerals segment held the largest share of the celiac disease treatment market with 40.16% market share due to the high demand to address nutritional deficiencies related to the condition. Malabsorption of vital nutrients such as iron, calcium, vitamin D, and B-complex vitamins occurs in patients with celiac disease due to chronic intestinal damage. Accordingly, vitamin and mineral supplementation continues to be an integral element of management, functioning to decrease symptoms such as anemia, weakness, and bone loss, and to enhance overall patient recuperation in conjunction with a gluten-free diet.
The gluten-degrading enzymes segment is expected to witness the fastest growth in the forecast period as a result of greater innovation in enzyme-based treatments for minimizing the severity of symptoms caused by gluten. These enzymes are being developed to break down leftover gluten that is ingested accidentally, serving as an extra layer of protection for celiac patients who often struggle with following strict diets. The fast uptake and growth of this category are being propelled by patient interest in adjunctive therapies that fit into their lifestyles as well as continued clinical exploration of enzyme effectiveness.
By Distribution Channel
In 2024, the retail pharmacies segment held the largest celiac disease treatment market Share of about 58.50%, owing to its widespread availability, customer credibility, and position as a first-line channel for over-the-counter supplements such as vitamins and minerals. Retail pharmacies are where patients go for rapid access to prescribed and non-prescription therapy, nutritionals, and advice from a pharmacist. For those suffering from celiac disease, retail pharmacies quickly turned into the most favorable outlet for drug therapy, given the convenience of physically acquiring products, not to mention the opportunity to have direct communication with healthcare providers.
The online pharmacies segment will be growing at the fastest rate during the forecast period as more and more consumers turn to digital healthcare, particularly in the post-pandemic scenario. Home delivery of convenience, wider product range availability, and subscription plans for frequent supplement requirements are advantages offered to celiac patients. Growing internet penetration, mobile app usage, and insight into gluten-free and therapeutic products available on the internet are all serving to drive the high growth in this segment as a viable and effective distribution platform.
Regional Analysis:
In 2024, North America dominated the celiac disease treatment market with a 39.24% market share due to the region's sophisticated healthcare infrastructure, high prevalence of the disease, and well-established treatment facilities. The U.S. is especially favored by a high rate of diagnosis, early diagnosis, and strong healthcare policies that facilitate easy access to treatment. In addition, the presence of key pharmaceutical players and a high prevalence of people with celiac disease also propels the growth of the market in North America, which is the largest regional contributor to the global market share.
Asia Pacific is the fastest-growing region in the global celiac disease treatment market with 12.75% CAGR, propelled by growing awareness of celiac disease, enhancing healthcare infrastructure, and increasing demand for gluten-free products. With increasing healthcare expenditures, growing access to diagnosis, and a rise in lifestyle disorders, the region is witnessing an uptrend in demand for celiac disease therapies. With developing economies in nations such as China, India, and Japan, increasing emphasis on patient education and therapy accessibility will drive quick market growth for this region.
Europe is experiencing rapid growth in the celiac disease treatment market due to increased awareness and improved access to healthcare on the continent. European countries have embraced advanced diagnostic techniques and are well-educated regarding celiac disease, leading to higher rates of diagnosis and treatment. The presence of advanced healthcare systems, high rates of gluten-free drug therapies, and growing demand for specialized treatments also contribute to the growth of the market in Europe. Moreover, continuous research and partnerships between healthcare providers and pharmaceutical firms are improving access to innovative therapies for celiac disease, driving market growth in the region.
Both the Middle East & Africa (MEA) and Latin America in 2024 showed moderate growth in the celiac disease treatment market due to growing awareness, enhancement in healthcare infrastructure, and an increase in demand for gluten-free foods.
In Latin America, Brazil and Argentina are experiencing increasing celiac disease diagnoses, facilitated by tighter regulations on gluten labeling and increased awareness of gluten-free living among consumers, driving the market growth in this region.
In the MEA region, countries such as Saudi Arabia and the UAE are stepping up efforts to improve diagnostic capacities and expand the availability of gluten-free products. These efforts are creating a more conducive climate for the development of the celiac disease treatment market.
Takeda Pharmaceutical Company Limited, Immunic Therapeutics, Innovate Biopharmaceuticals, BioLineRx Ltd., Amgen Inc., ZEDIRA GmbH, Novartis, Cour Pharmaceuticals, ImmunogenX, Anokion SA, Topas Therapeutics, and other players.
February 2024 – Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Xolair (omalizumab) to decrease allergic reactions, including anaphylaxis, due to accidental ingestion of one or more foods. The approval is for both adult and pediatric patients 1 year of age and older with IgE-mediated food allergies.
November 2024 – Immunic, Inc., a biopharmaceutical company developing oral drugs for chronic inflammatory and autoimmune disorders, reported that data from its Phase 1/1b clinical trial of IMU-856 were published in The Lancet Gastroenterology & Hepatology. IMU-856 is an orally active, systemically absorbed small molecule aimed at SIRT6 (Sirtuin 6).
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 682.40 million |
| Market Size by 2032 | USD 1667.73 million |
| CAGR | CAGR of 11.88% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Treatment (Vitamins & Minerals, Gluten Degrading Enzymes, Symptomatic Treatment [Anti-inflammatory Drugs, Antihistamines, Others], Other Treatments) • By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Takeda Pharmaceutical Company Limited, Immunic Therapeutics, Innovate Biopharmaceuticals, BioLineRx Ltd., Amgen Inc., ZEDIRA GmbH, Novartis, Cour Pharmaceuticals, ImmunogenX, Anokion SA, Topas Therapeutics, and other players. |
Ans: The Celiac Disease Treatment Market is expected to grow at a CAGR of 11.88% from 2025 to 2032.
Ans: The Celiac Disease Treatment Market was USD 682.40 million in 2024 and is expected to reach USD 1667.73 million by 2032.
Ans: Increasing awareness and early diagnosis are propelling the market growth.
Ans: The “Vitamins & Minerals” segment dominated the Celiac Disease Treatment Market.
Ans: North America dominated the Celiac Disease Treatment Market in 2024.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2024)
5.2 Diagnosis and Treatment Initiation Trends (2024), by Region
5.3 Gluten-Free Product Adoption and Supplement Usage (2020–2032)
5.4 Healthcare Spending, by Region (Government, Commercial, Private, Out-of-Pocket), 2024
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion Plans and New Product Launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Celiac Disease Treatment Market Segmentation By Treatment
7.1 Chapter Overview
7.2 Vitamins & Minerals
7.2.1 Vitamins & Minerals Market Trend Analysis (2021-2032)
7.2.2 Vitamins & Minerals Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Gluten-Degrading Enzymes
7.3.1 Gluten Degrading Enzymes Market Trends Analysis (2021-2032)
7.3.2 Gluten Degrading Enzymes Market Size Estimates and Forecasts to 2032 (USD Million)
7.4 Symptomatic Treatment
7.4.1 Symptomatic Treatment Market Trends Analysis (2021-2032)
7.4.2 Symptomatic Treatment Market Size Estimates and Forecasts to 2032 (USD Million)
7.5 Other Treatments
7.5.1 Other Treatments Market Trends Analysis (2021-2032)
7.5.2 Other Treatments Market Size Estimates and Forecasts to 2032 (USD Million)
8. Celiac Disease Treatment Market Segmentation By Distribution Channel
8.1 Chapter Overview
8.2 Hospital Pharmacies
8.2.1 Hospital Pharmacies Market Trends Analysis (2021-2032)
8.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Retail Pharmacies
8.3.1 Retail Pharmacies Market Trends Analysis (2021-2032)
8.3.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Online Pharmacies
8.4.1 Online Pharmacies Market Trends Analysis (2021-2032)
8.4.2 Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Million)
8.5 Other Distribution Channels
8.5.1 Other Distribution Channels Market Trends Analysis (2021-2032)
8.5.2 Other Distribution Channels Market Size Estimates and Forecasts to 2032 (USD Million)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Celiac Disease Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Million)
9.2.3 North America Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.2.4 North America Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.2.5 USA
9.2.5.1 USA Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.2.5.2 USA Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.2.6 Canada
9.2.6.1 Canada Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.2.6.2 Canada Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.2.7 Mexico
9.2.7.1 Mexico Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.2.7.2 Mexico Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.3 Europe
9.3.1 Trends Analysis
9.3.2 Europe Celiac Disease Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Million)
9.3.3 Europe Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.3.4 Europe Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.3.5 Germany
9.3.5.1 Germany Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.3.5.2 Germany Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.3.6 France
9.3.6.1 France Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.3.6.2 France Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.3.7 UK
9.3.7.1 UK Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.3.7.2 UK Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.3.8 Italy
9.3.8.1 Italy Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.3.8.2 Italy Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.3.9 Spain
9.3.9.1 Spain Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.3.9.2 Spain Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.3.10 Poland
9.3.10.1 Poland Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.3.10.2 Poland Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.3.11 Turkey
9.3.11.1 Turkey Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.3.11.2 Turkey Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.3.12 Rest of Europe
9.3.12.1 Rest of Europe Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.3.12.2 Rest of Europe Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Celiac Disease Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Million)
9.4.3 Asia Pacific Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.4.4 Asia Pacific Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.4.5 China
9.4.5.1 China Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.4.5.2 China Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.4.6 India
9.4.5.1 India Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.4.5.2 India Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.4.5 Japan
9.4.5.1 Japan Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.4.5.2 Japan Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.4.6 South Korea
9.4.6.1 South Korea Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.4.6.2 South Korea Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.4.7 Singapore
9.4.7.1 Singapore Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.4.7.2 Singapore Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
8.4.8 Australia
8.4.8.1 Australia Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
8.4.8.2 Australia Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.4.9 Rest of Asia Pacific
9.4.9.1 Rest of Asia Pacific Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.4.9.2 Rest of Asia Pacific Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.5 Middle East & Africa
9.5.1 Trends Analysis
9.5.2 Middle East & Africa Celiac Disease Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Million)
9.5.3 Middle East & Africa Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.5.4 Middle East & Africa Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.5.5 UAE
9.5.5.1 UAE Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.5.5.2 UAE Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.5.6 Saudi Arabia
9.5.6.1 Saudi Arabia Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.5.6.2 Saudi Arabia Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.5.7 Qatar
9.5.7.1 Qatar Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.5.7.2 Qatar Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.5.8 South Africa
9.5.8.1 South Africa Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.5.8.2 South Africa Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.5.9 Middle East & Africa
9.5.9.1 Middle East & Africa Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.5.9.2 Middle East & Africa Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Celiac Disease Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Million)
9.6.3 Latin America Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.6.4 Latin America Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.6.5 Brazil
9.6.5.1 Brazil Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.6.5.2 Brazil Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.6.6 Argentina
9.6.6.1 Argentina Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.6.6.2 Argentina Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
9.6.7 Rest of Latin America
9.6.7.1 Rest of Latin America Celiac Disease Treatment Market Estimates and Forecasts, By Treatment (2021-2032) (USD Million)
9.6.7.2 Rest of Latin America Celiac Disease Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Million)
10. Company Profiles
10.1 Takeda Pharmaceutical Company Limited
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Product / Services Offered
10.1.4 SWOT Analysis
10.2 Immunic Therapeutics
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Product/ Services Offered
10.2.4 SWOT Analysis
10.3 Innovate Biopharmaceuticals
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Product/ Services Offered
10.3.4 SWOT Analysis
10.4 BioLineRx Ltd.
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Product/ Services Offered
10.4.4 SWOT Analysis
10.5 Amgen Inc.,
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Product/ Services Offered
10.5.4 SWOT Analysis
10.6 ZEDIRA GmbH
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Product/ Services Offered
10.6.4 SWOT Analysis
10.7 Novartis
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Product/ Services Offered
10.7.4 SWOT Analysis
10.8 Cour Pharmaceuticals
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Product/ Services Offered
10.8.4 SWOT Analysis
10.9 ImmunogenX
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Product/ Services Offered
10.9.4 SWOT Analysis
10.10 Anokion SA.
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Product/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Treatment
Vitamins & Minerals
Gluten Degrading Enzymes
Symptomatic Treatment (Anti-inflammatory Drugs, Antihistamines, Others)
Other Treatments
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
